Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (71-80 of 177) with videos related to

Pageof 18
Sort By:
Acta Neuropathologica|September 2, 2019
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomasFrank Brand, Alisa Förster, Anne Christians, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Frontiers in Oncology|November 11, 2021
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the PrognosisCyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Cell Reports|August 24, 2017
Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in CancerMarco R Cosenza, Anna Cazzola, Annik Rossberg, et al.
Pageof 18

Showing results (71-80 of 177) with videos related to

Sort By:
Pageof 18
Acta Neuropathologica|September 2, 2019
FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomasFrank Brand, Alisa Förster, Anne Christians, et al.
Haematologica|November 28, 2015
Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myelomaNiels Weinhold, Desiree Kirn, Anja Seckinger, et al.
Frontiers in Oncology|November 11, 2021
Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the PrognosisCyrus Khandanpour, Christine Eisfeld, Subbaiah Chary Nimmagadda, et al.
Haematologica|March 22, 2015
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myelomaElias K Mai, Thomas Hielscher, Jost K Kloth, et al.
Cancer Medicine|December 8, 2025
Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose MelphalanAnna Fleischer, Magdalena Roll, Jan H Frenking, et al.
Molecular Cancer Therapeutics|December 10, 2020
HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma CellsVianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, et al.
Cancers|September 28, 2023
Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE TrialLisa B Leypoldt, Maria Gavriatopoulou, Britta Besemer, et al.
Cancer Research|June 11, 2009
Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myelomaJing Zhang, Martin Sattler, Giovanni Tonon, et al.
The FEBS Journal|April 25, 2023
Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myelomaNatalie Berghaus, Sarah Schreiner, Alexandra M Poos, et al.
Cell Reports|August 24, 2017
Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in CancerMarco R Cosenza, Anna Cazzola, Annik Rossberg, et al.
Pageof 18